UCB (OTCMKTS:UCBJY) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s Why

UCB SA (OTCMKTS:UCBJYGet Free Report) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $95.59 and traded as low as $81.63. UCB shares last traded at $81.73, with a volume of 39,804 shares changing hands.

UCB Stock Down 7.5 %

The stock’s 50 day simple moving average is $96.07 and its 200-day simple moving average is $95.64. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

UCB Company Profile

(Get Free Report)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

See Also

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.